#USA #New York #Microtech #Medinol #Atrial Microsensor

Microtech's Innovative Step Forward in Medical Technology

Microtech, a subsidiary of Medinol, recently announced an important milestone in medical technology with the first implantations of its atrial-pressure microsensor in the United States. Conducted on May 16, 2025, these pioneering surgeries took place at New York-Presbyterian/Columbia University Irving Medical Center and were led by Dr. Koji Takeda, the Surgical Director for Adult Heart Transplantation.

The atrial microsensor represents a cutting-edge development in cardiac care, characterized by its remarkably small size and entirely passive design. Notably, it does not include any electronic components or antennas, instead relying on ultrasound for data transmission. This innovative approach allows the microsensor to function as an independent device or to be integrated alongside existing medical implants, transforming standard devices into smart, multifunctional diagnostic tools.

In total, two microsensors were implanted, adding to an existing five microsensors that were previously implanted in Israel under similar circumstances. Dr. Takeda remarked on the procedure's efficiency, noting that it takes approximately five minutes and requires only minor alterations to the existing left ventricular assist device (LVAD) implantation procedures.

This advanced technology opens new doors in patient monitoring. Dr. Nir Uriel, the Director of Advanced Heart Failure and Cardiac Transplantation at NewYork-Presbyterian and Principal Investigator for the Microtech First in Human (FIH) study, pointed out the significant benefits of the microsensor: "The ability to monitor both left and right cardiac pressures non-invasively will greatly enhance our capability to optimize patient care, moving beyond just addressing symptoms to implementing parameter-based therapies." He emphasized the preliminary success of the sensors, stating they have allowed for easy, repeatable, and accurate pressure measurements across all study participants.

The scope of the Microtech FIH study is set to enroll around 15 patients across the U.S. and Israel. Dr. Yoram Richter, CEO of Medinol, expressed enthusiasm about the ongoing study and the sensor's performance. He stated, "We are excited about the progress made so far and are hopeful this will continue to show the feasibility, usability, and accuracy of our system. At the same time, we are investigating how to integrate microsensors within existing medical devices, thereby fulfilling the true potential of this technology."

About Medinol

Medinol is at the forefront of transforming how diseases are diagnosed and treated. The company is committed to developing innovative devices that significantly reduce complications in medical procedures and provide real-time physiological insights via implantable sensors. Medinol continuously challenges conventional technologies and practices, looking towards the future to create devices that expand the operational reach of healthcare providers.

For more information, visit Medinol's website or contact Jeff Roach, Chief Commercial Officer, at [email protected].